209 related articles for article (PubMed ID: 34106431)
1. Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience.
Silvestro M; Orologio I; Bonavita S; Scotto di Clemente F; Fasano C; Tessitore A; Tedeschi G; Russo A
Pain Ther; 2021 Dec; 10(2):1203-1214. PubMed ID: 34106431
[TBL] [Abstract][Full Text] [Related]
2. Refractory migraine profile in CGRP-monoclonal antibodies scenario.
Silvestro M; Tessitore A; Scotto di Clemente F; Battista G; Tedeschi G; Russo A
Acta Neurol Scand; 2021 Sep; 144(3):325-333. PubMed ID: 34019304
[TBL] [Abstract][Full Text] [Related]
3. Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary.
van Casteren DS; Verhagen IE; van der Arend BWH; van Zwet EW; MaassenVanDenBrink A; Terwindt GM
Neurology; 2021 Oct; 97(17):e1661-e1671. PubMed ID: 34493613
[TBL] [Abstract][Full Text] [Related]
4. Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.
Blumenfeld A; Durham PL; Feoktistov A; Hay DL; Russo AF; Turner I
Neurol Ther; 2021 Dec; 10(2):469-497. PubMed ID: 34076848
[TBL] [Abstract][Full Text] [Related]
5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
Jiang Y; Huang ZL
Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
[TBL] [Abstract][Full Text] [Related]
8. Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies.
Verhagen IE; de Vries Lentsch S; van der Arend BWH; le Cessie S; MaassenVanDenBrink A; Terwindt GM
Eur J Neurol; 2023 Jul; 30(7):2117-2121. PubMed ID: 36941533
[TBL] [Abstract][Full Text] [Related]
9. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines.
Katsuki M; Kashiwagi K; Kawamura S; Koh A
Cureus; 2023 Jan; 15(1):e33689. PubMed ID: 36788886
[TBL] [Abstract][Full Text] [Related]
12. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.
Corasaniti MT; Lawrence GW; Bagetta G; Iannacchero R; Tarsitano A; Monteleone A; Pagliaro M; Tonin P; Sandrini G; Nicotera P; Scuteri D
Front Pharmacol; 2023; 14():1296577. PubMed ID: 38152694
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres.
Granella F; Sances G; Allais G; Nappi RE; Tirelli A; Benedetto C; Brundu B; Facchinetti F; Nappi G
Cephalalgia; 2004 Sep; 24(9):707-16. PubMed ID: 15315526
[TBL] [Abstract][Full Text] [Related]
14. Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization.
Alpuente A; Gallardo VJ; Asskour L; Caronna E; Torres-Ferrus M; Pozo-Rosich P
J Headache Pain; 2024 Apr; 25(1):58. PubMed ID: 38637736
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
16. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
17. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
18. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
19. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
